Blue Light for Diverticulitis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diverticulitis+2 More
Blue Light - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial found that blue light exposure was able to modulate the host response to injury and critical illness, potentially improving outcome.

Eligible Conditions
  • Diverticulitis
  • Pneumonia
  • Appendicitis

Treatment Effectiveness

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: comparing time of randomization and at 72 hours after randomization

Hour 72
All Cohorts: change in serum cytokine concentrations
Appendicitis and Diverticulitis: change in systemic inflammation
Pneumonia: change in bronchoalveolar lavage (BAL) bacteria concentration
Pneumonia: change in bronchoalveolar lavage (BAL) neutrophil concentration
from time of randomization to 28-days after randomization
Appendicitis and Diverticulitis: intraabdominal abscess formation

Trial Safety

Trial Design

6 Treatment Groups

Appendicitis: Ambient Light
1 of 6
Pneumonia: Ambient Light
1 of 6
Diverticulitis: Ambient Light
1 of 6
Appendicitis: Blue Light
1 of 6
Diverticulitis: Blue Light
1 of 6
Pneumonia: Blue Light
1 of 6

Active Control

Experimental Treatment

72 Total Participants · 6 Treatment Groups

Primary Treatment: Blue Light · No Placebo Group · N/A

Appendicitis: Blue Light
Other
Experimental Group · 1 Intervention: Blue Light · Intervention Types: Other
Diverticulitis: Blue Light
Other
Experimental Group · 1 Intervention: Blue Light · Intervention Types: Other
Pneumonia: Blue Light
Other
Experimental Group · 1 Intervention: Blue Light · Intervention Types: Other
Appendicitis: Ambient LightNoIntervention Group · 1 Intervention: Appendicitis: Ambient Light · Intervention Types:
Pneumonia: Ambient LightNoIntervention Group · 1 Intervention: Pneumonia: Ambient Light · Intervention Types:
Diverticulitis: Ambient LightNoIntervention Group · 1 Intervention: Diverticulitis: Ambient Light · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: comparing time of randomization and at 72 hours after randomization

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,601 Previous Clinical Trials
6,286,252 Total Patients Enrolled
Matthew R Rosengart, MD MPHPrincipal InvestigatorUniversity of Pittsburgh
2 Previous Clinical Trials
10,192 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.